ComparisonHere are results from a P1/2 trial finished in 2019. Similar results to ONC, and this led to the initiation of a 700+ patient P3 presently enrolling.
In fact, ONC's results are much better (1CR and 8PR in 13 patients) vs. (1 CR and 10 PR in 32 patients).
There really can be no doubt that ONC is heading very quickly to a P3 in PDAC.
Partnership/buyout on the way.
https://www.targetedonc.com/view/frontline-nalirifox-regimen-demonstrates-promising-activity-in-advanced-pdac